mRNA Cancer Vaccines

A stock that doubles on one readout was telling you what it thought of the odds

Moderna shares rose more than 100% after the melanoma Phase 3 hit, and a co-founder's net worth went from $730 million to $1.7 billion. The wealth number is a risk gauge, not a story.